Ovarian cancer, also known as the silent killer, has always been a challenging disease with poor outcomes despite decades of research. Ovarian cancer is the fifth most common cause of cancer-related deaths in women in the US. Each year, about 22,000 women across the country are diagnosed with the disease, and the majority (61%) are diagnosed in late stages, when the survival rate is low, resulting in just over 14,000 deaths per year.1 When ovarian cancer is detected at the earliest stage, the 5-year survival rate is 92%.2
The ROCA Test
The ROCA Test is a simple blood test that helps doctors determine if a woman might have ovarian cancer. It is intended for postmenopausal women over 50 years and those at high risk of the disease to routinely measure their individual risk of developing the disease.
The ROCA Test has been clinically evaluated in several trials involving over 200,000 women. It is used as a first step in detecting ovarian cancer, often before symptoms appear. The largest trial has lasted 15 years and has shown:3,4,5
- Sensitivity: 85.8%3
- Specificity: 99.8%3
- Detects two times more ovarian cancers when followed up with an ultrasound scan than the CA-125 test (using a fixed cut-off)4
- Detects more ovarian cancers at an earlier stage5
Disclaimer: Interpretation of the ROCA Test results is based upon outcomes data from clinical trials. The ROCA Test can detect 85.8% of ovarian cancers, if a patient meets the eligibility criteria.4 If a patient falls outside of the eligibility criteria, Abcodia cannot guarantee the test results. Any clinical assessment and determination of a course of treatment are solely the responsibility of a patient’s physician. Abcodia does not offer or provide medical judgment. It is recommended that all ROCA Test results be reviewed by a patient with their physician.
- American Cancer Society, “What are the key statistics about ovarian cancer?,”http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-key-statistics
- American Cancer Society, “Survival rates for ovarian cancer, by stage”. http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-survival-rates
- Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol; 10: 327- 40, 2009.
- Menon U, Ryan A, Kalsi J, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 2015; 33: 2062–71.
- Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016; 387: 944 – 956.